NATCO Pharma Launches Semaglutide Generic at 90% Discount

A New Era for Diabetes Treatment in India

Hyderabad-based NATCO Pharma has launched its generic version of semaglutide, a widely used drug for type-2 diabetes, immediately following the expiration of the innovator's patent on March 20, 2026. The company's entry into this market is marked by an aggressive pricing strategy, offering the treatment at a discount of up to 90% compared to the original brand. This move is expected to significantly increase patient access to advanced GLP-1 therapy and trigger intense competition among domestic drugmakers.

Semaglutide, part of the GLP-1 receptor agonist class of drugs, is prescribed as an adjunct to diet and exercise for adults with insufficiently controlled type-2 diabetes. Its popularity has surged globally for both its effectiveness in managing blood sugar levels and its benefits in weight management. The patent expiry in India has opened the market to generic manufacturers, setting the stage for a major shift in pricing and availability.

NATCO's Aggressive Pricing and Product Strategy

NATCO is introducing its generic semaglutide under the brand names "Semanat" and "Semafull". The company is initially launching the product in multi-dose vials, a first for the Indian market. This format is priced to be highly accessible. The monthly cost for the 2mg and 4mg strength vials is set at ₹1,290, while the 8mg strength vial is priced at ₹1,750. According to the company, this pricing makes its vial formulation approximately 70% cheaper than existing pen devices and 90% cheaper than the innovator's product.

To cater to patient convenience, NATCO also plans to launch a pen device version in April 2026. The pricing for the pen is expected to be ₹4,000 for the 2mg strength, ₹4,200 for the 4mg strength, and ₹4,500 for the 8mg strength. This dual-format strategy allows the company to cater to different segments of the market, balancing affordability with ease of use.

Regulatory Approval and Strategic Alliances

NATCO Pharma received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market its generic semaglutide. The approval was granted for both multi-dose vials and pen devices after the company successfully completed clinical studies demonstrating bioequivalence with the originator product. This regulatory clearance paved the way for the day-one launch.

To expand its market reach, NATCO has entered into a strategic partnership with Eris Lifesciences. Under this agreement, Eris will co-market the semaglutide formulation in India under its own brand name, "Sundae", at the same price points. This collaboration leverages Eris's strong commercial presence in the diabetes segment and NATCO's manufacturing capabilities, aiming to maximize distribution across the country.

Market Impact and Competitive Landscape

The expiration of the semaglutide patent has opened the floodgates for competition. Several major Indian pharmaceutical companies, including Sun Pharma, Dr. Reddy's Laboratories, Zydus Lifesciences, and Cipla, have secured regulatory approvals and are expected to launch their own generic versions. This influx of competitors is anticipated to drive prices down further and expand the market significantly. Analysts predict the market could grow tenfold in the coming years as affordability improves.

Sun Pharma has already announced its intention for a day-one launch with a pre-filled pen format, signaling the intense competition NATCO will face. The entry of multiple players is beneficial for patients, who previously faced monthly treatment costs of over ₹10,000. With generic options, this cost is expected to fall sharply, improving long-term compliance and treatment outcomes.

Stock Market Reaction

The market responded positively to NATCO Pharma's announcement. On March 20, 2026, the company's stock surged, trading 2.5% to 3.06% higher at around ₹966 per share. This reflects investor confidence in the company's ability to capture a significant share of the lucrative semaglutide market with its first-mover advantage and competitive pricing.

Conclusion

NATCO Pharma's launch of generic semaglutide at a disruptive price point marks a pivotal moment for diabetes care in India. By making this advanced therapy more affordable, the company is poised to improve treatment access for millions of patients. The strategic partnership with Eris Lifesciences and the planned launch of a pen device further strengthen its market position. However, with a wave of competitors entering the fray, the coming months will be critical in shaping the landscape of India's generic semaglutide market.